-
Signature
-
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
-
Issuer symbol
-
ROIV
-
Transactions as of
-
15 Oct 2025
-
Net transactions value
-
-$973,082
-
Form type
-
4
-
Filing time
-
17 Oct 2025, 21:00:12 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Venker Eric |
President & Immunovant CEO |
C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM |
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker |
17 Oct 2025 |
0001801917 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ROIV |
Common Shares |
Options Exercise |
$6,572,726 |
+414,683 |
+28% |
$15.85 |
1,919,642 |
15 Oct 2025 |
Direct |
|
| transaction |
ROIV |
Common Shares |
Sale |
$7,020,583 |
-414,683 |
-22% |
$16.93 |
1,504,959 |
15 Oct 2025 |
Direct |
F1 |
| transaction |
ROIV |
Common Shares |
Options Exercise |
$5,044,770 |
+318,282 |
+21% |
$15.85 |
1,823,241 |
16 Oct 2025 |
Direct |
|
| transaction |
ROIV |
Common Shares |
Sale |
$5,426,708 |
-318,282 |
-17% |
$17.05 |
1,504,959 |
16 Oct 2025 |
Direct |
F1 |
| transaction |
ROIV |
Common Shares |
Options Exercise |
$1,876,925 |
+118,418 |
+7.9% |
$15.85 |
1,623,377 |
17 Oct 2025 |
Direct |
|
| transaction |
ROIV |
Common Shares |
Sale |
$2,020,211 |
-118,418 |
-7.3% |
$17.06 |
1,504,959 |
17 Oct 2025 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
ROIV |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-414,683 |
-49% |
$0.000000 |
436,700 |
15 Oct 2025 |
Common Stock |
414,683 |
$15.85 |
Direct |
F2 |
| transaction |
ROIV |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-318,282 |
-73% |
$0.000000 |
118,418 |
16 Oct 2025 |
Common Stock |
318,282 |
$15.85 |
Direct |
F2 |
| transaction |
ROIV |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-118,418 |
-100% |
$0.000000 |
0 |
17 Oct 2025 |
Common Stock |
118,418 |
$15.85 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: